However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.